Vancomycin is commonly under-dosed in critically ill children and neonates
- PMID: 31378957
- PMCID: PMC6848905
- DOI: 10.1111/bcp.14084
Vancomycin is commonly under-dosed in critically ill children and neonates
Abstract
Aims: Vancomycin is frequently used in critically ill children in whom the drug pharmacokinetics are significantly altered as a result of changes in renal clearance and volume of distribution. Therapeutic drug monitoring (TDM) is recommended to achieve vancomycin trough concentrations between 10 and 20 mg/L. In this study we reviewed vancomycin dosing, TDM and treatment outcomes in paediatric and neonatal intensive care unit patients.
Methods: We reviewed the medical records of all patients receiving intravenous vancomycin in a tertiary paediatric and neonatal intensive care unit over a 10-month period. Demographic, vancomycin dosing, TDM and drug-related adverse effects data were collected.
Results: In total, 115 children received 126 courses of vancomycin and had at least 1 TDM blood sample taken at steady state. In only 38/126 (30%) courses was the target concentration (10-20 mg/L) achieved at the initial steady state trough sample. Of the 88 courses that had initial trough concentrations outside the target range, the dose was adjusted in only 49 (56%). Overall, minimum doses of 30 mg/kg/day in neonates with a corrected gestational age of <35 weeks, and 50 mg/kg/day in older children, were required to achieve target vancomycin concentrations. Vancomycin-attributable nephrotoxicity occurred in 10/126 (8%) courses and there were no episodes of red man syndrome.
Conclusion: In critically ill children, individualised dosing is needed. In the absence of Bayesian model-based dosing, in children with normal renal function, empiric vancomycin doses of at least 30 mg/kg/day in neonates of <35 weeks corrected gestational age, and 50 mg/kg/day in older children, should be considered. Optimisation of TDM practices through the development of protocols, ideally built into electronic medical records, should be considered.
Keywords: children; dosing; glycopeptide; neonates; pharmacokinetics; therapeutic drug monitoring.
© 2019 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
Conflict of interest statement
This study was conducted as part of routine work. There are no competing interest to declare.
Figures
References
-
- Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin‐resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52(3):285‐292. - PubMed
-
- Royal Children's Hospital . Vancomycin. In, Melbourne, Australia.
-
- Jung Y, Song KH, Cho J, et al. Area under the concentration‐time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin‐resistant Staphylococcus aureus bacteraemia. Int J Antimicrob Agents. 2014;43(2):179‐183. - PubMed
-
- Jeffres MN, Isakow W, Doherty JA, Micek ST, Kollef MH. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care‐associated methicillin‐resistant Staphylococcus aureus pneumonia. Clin Ther. 2007;29(6):1107‐1115. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
